Research Progress on Natural Products Alleviating Liver Inflammation and Fibrosis via NF-κB Pathway
- PMID: 39576739
- DOI: 10.1002/cbdv.202402248
Research Progress on Natural Products Alleviating Liver Inflammation and Fibrosis via NF-κB Pathway
Abstract
Liver fibrosis is a key pathological process in chronic liver diseases, regulated by various cytokines and signaling pathways. Among these, the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway plays a significant role in the initiation and progression of liver fibrosis. Recently, natural products have garnered attention as potential anti-fibrotic agents. This review highlights recent studies on how natural products, including flavonoids, terpenoids, polysaccharides, phenols, alkaloids, quinones, phenylpropanoids, steroids, and nitrogen compounds, mitigate liver fibrosis by modulating the NF-κB signaling pathway. Specifically, it examines how these natural products influence NF-κB activation, nuclear translocation, and downstream signaling, thereby inhibiting inflammatory responses, reducing apoptosis, and regulating hepatic stellate cell (HSC) activity, ultimately achieving therapeutic effects against liver fibrosis. A deeper understanding of the mechanisms by which natural products regulate the NF-κB signaling pathway can provide crucial theoretical foundations and valuable insights for the development of novel anti-fibrotic drugs.
Keywords: liver fibrosis; natural products; nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) pathway.
© 2024 Wiley‐VHCA AG, Zurich, Switzerland.
References
-
- S. L. Friedman and M. Pinzani, “Hepatic Fibrosis 2022: Unmet Needs and a Blueprint for the Future,” Hepatology 75, no. 2 (2022): 473–488.
-
- S. Seen, “Chronic Liver Disease and Oxidative Stress—A Narrative Review,” Expert Review of Gastroenterology & Hepatology 15, no. 9 (2021): 1021–1035.
-
- T. Luangmonkong, S. Suriguga, H. A. M. Mutsaers, G. M. M. Groothuis, P. Olinga, and M. Boersema, “Targeting Oxidative Stress for the Treatment of Liver Fibrosis,” Reviews of Physiology, Biochemistry and Pharmacology 175 (2018): 71–102.
-
- D. Ezhilarasan, “Oxidative Stress is Bane in Chronic Liver Diseases: Clinical and Experimental Perspective,” Arab Journal of Gastroenterology 19, no. 2 (2018): 56–64.
-
- L. Hammerich and F. Tacke, “Hepatic Inflammatory Responses in Liver Fibrosis,” Nature Reviews Gastroenterology & Hepatology 20, no. 10 (2023): 633–646.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
